Day One Biopharmaceuticals (DAWN) News Today $7.93 +0.31 (+4.07%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$7.88 -0.05 (-0.69%) As of 07:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Boxer Capital Management LLC Acquires Shares of 1,189,943 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Boxer Capital Management LLC purchased a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,189,943 shares of the company's stock,May 4 at 6:25 AM | marketbeat.comPrice T Rowe Associates Inc. MD Sells 838,751 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Price T Rowe Associates Inc. MD lessened its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 33.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,706,112 shares of the company's stoMay 4 at 4:11 AM | marketbeat.comDay One Biopharmaceuticals (DAWN) to Release Earnings on TuesdayMay 4 at 1:53 AM | americanbankingnews.comRA Capital Management L.P. Cuts Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)RA Capital Management L.P. lessened its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 26.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,755,577 shares of the company's stock after selling 2,116,144 shares duMay 3 at 7:49 AM | marketbeat.comDay One Biopharmaceuticals (DAWN) Projected to Post Earnings on TuesdayDay One Biopharmaceuticals (NASDAQ:DAWN) will be releasing its Q1 2025 earnings after the market closes on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-day-one-biopharmaceuticals-inc-stock/)May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 100,000 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Adage Capital Partners GP L.L.C. cut its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 11.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 800,000 shares of the company's stock after selling 100,000 shares during tApril 30, 2025 | marketbeat.comAnalysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $32.29April 30, 2025 | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by AnalystsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned an average rating of "Buy" from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strongApril 28, 2025 | marketbeat.comRenaissance Technologies LLC Purchases 148,900 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Renaissance Technologies LLC grew its holdings in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 157.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 243,740 shares of the company's stock after buying an addApril 26, 2025 | marketbeat.comResearch Analysts Offer Predictions for DAWN Q1 EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Wedbush decreased their Q1 2025 EPS estimates for Day One Biopharmaceuticals in a report issued on Monday, April 21st. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.45) for the quarteApril 25, 2025 | marketbeat.comWedbush Brokers Lower Earnings Estimates for DAWNApril 25, 2025 | americanbankingnews.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 5% - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Up 5% - Should You Buy?April 23, 2025 | marketbeat.comMarshall Wace LLP Buys Shares of 1,097,762 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Marshall Wace LLP purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 1,097,762 shares of the company's stock, valued at approximately $13,909,000.April 23, 2025 | marketbeat.comDay One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025April 22, 2025 | globenewswire.comDay One Biopharmaceuticals price target lowered to $21 from $24 at BofAApril 18, 2025 | markets.businessinsider.comBank of America Securities Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)April 17, 2025 | markets.businessinsider.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 2.7% - Here's What HappenedDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 2.7% - Should You Sell?April 16, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Acquired by Fmr LLCFmr LLC increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 73.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,887,467 shares of thApril 15, 2025 | marketbeat.comNorges Bank Acquires Shares of 169,000 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Norges Bank bought a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 169,000 shares of the company's stock, valued at approximatelyApril 14, 2025 | marketbeat.com100,735 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by CenterBook Partners LPCenterBook Partners LP acquired a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 100,735 shares of the company's stock, valued at approximatelyApril 13, 2025 | marketbeat.comTrexquant Investment LP Purchases New Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Trexquant Investment LP purchased a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 87,972 shares of the company's stock, valued at approximately $1,115,000. Trexquant InvesApril 13, 2025 | marketbeat.comVanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Vanguard Group Inc. cut its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 0.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,848,923 shares of the company's stock after sellApril 13, 2025 | marketbeat.comDay One Biopharmaceuticals Pullback Is A Potential Buying OpportunityApril 11, 2025 | seekingalpha.comDay One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comExodusPoint Capital Management LP Buys Shares of 215,137 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)ExodusPoint Capital Management LP purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 215,137 shares of thApril 9, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year Low - Here's What HappenedDay One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comHC Wainwright Analysts Decrease Earnings Estimates for DAWNDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Investment analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Day One Biopharmaceuticals in a research report issued on Thursday, April 3rd. HC Wainwright analyst A. Maldonado now anticipates that the companyApril 8, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN)HC Wainwright restated a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday.April 5, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of "Buy" by BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has been given an average rating of "Buy" by the eight research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. ThApril 3, 2025 | marketbeat.comJonesTrading Sticks to Their Buy Rating for Day One Biopharmaceuticals (DAWN)April 2, 2025 | markets.businessinsider.comDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low - Should You Sell?Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year Low - Here's What HappenedApril 1, 2025 | marketbeat.comPictet Asset Management Holding SA Increases Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Pictet Asset Management Holding SA raised its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 17.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,490,064 shares of the company's stock after buying an addiApril 1, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Holdings Lifted by BIT Capital GmbHBIT Capital GmbH increased its holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 41.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,714 shares of the company'sMarch 28, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Given New $27.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating for the company in a research report on Tuesday.March 26, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon CorpBank of New York Mellon Corp lifted its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 43.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 244,829 shares of the company's stock after purchasing an additional 74,March 20, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Invests $525,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Skandinaviska Enskilda Banken AB publ acquired a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 41,771 shares ofMarch 18, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 1.7% - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 1.7% - What's Next?March 15, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low - Should You Sell?Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low - What's Next?March 12, 2025 | marketbeat.comJackson Creek Investment Advisors LLC Buys Shares of 103,592 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)Jackson Creek Investment Advisors LLC bought a new position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 103,592 shares of the company's stock, valued at appMarch 8, 2025 | marketbeat.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of "Buy" from BrokeragesDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rMarch 8, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst DowngradeDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 5.5% Following Analyst DowngradeMarch 7, 2025 | marketbeat.comDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Here's WhyDay One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up - Time to Buy?March 6, 2025 | marketbeat.comJPMorgan Chase & Co. Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock PriceJPMorgan Chase & Co. lowered their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research report on Wednesday.March 6, 2025 | marketbeat.comDay One Biopharmaceuticals price target lowered to $34 from $39 at JPMorganMarch 5, 2025 | markets.businessinsider.comDay One Biopharmaceuticals, Inc. (DAWN): A Bull Case TheoryMarch 5, 2025 | msn.comDay One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low - What's Next?Day One Biopharmaceuticals (NASDAQ:DAWN) Hits New 1-Year Low - Here's WhyMarch 4, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for DAWN EarningsDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - HC Wainwright lifted their Q1 2025 earnings per share estimates for Day One Biopharmaceuticals in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Maldonado now anticipates that the company will post eaMarch 1, 2025 | marketbeat.comWhat is Wedbush's Forecast for DAWN Q1 Earnings?Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Wedbush decreased their Q1 2025 earnings per share (EPS) estimates for Day One Biopharmaceuticals in a report released on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.43) per shaMarch 1, 2025 | marketbeat.comOppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)February 27, 2025 | markets.businessinsider.comDay One price target lowered to $30 from $34 at JonesResearchFebruary 27, 2025 | markets.businessinsider.com Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address DAWN Media Mentions By Week DAWN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DAWN News Sentiment▼1.070.73▲Average Medical News Sentiment DAWN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DAWN Articles This Week▼74▲DAWN Articles Average Week Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Merus News Today Crinetics Pharmaceuticals News Today Scholar Rock News Today Akero Therapeutics News Today Viking Therapeutics News Today Xenon Pharmaceuticals News Today Catalyst Pharmaceuticals News Today MorphoSys News Today Protagonist Therapeutics News Today HUTCHMED News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DAWN) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DAWN Stock Free DAWN Stock Alerts